Ocular Therapeutix shares are trading higher Thursday after reports suggested Sanofi is preparing a revised bid for the ...

Ocular Therapeutix’s lead asset is Axpaxli, being developed for wet age-related macular degeneration. A Phase III study is ...

Ocular Therapeutix (OCUL) stock surges on rumors that Sanofi (SNY) is readying an improved bid to take over the company. Read ...

Sanofi (EU:SAN) is reportedly preparing to submit a higher takeover proposal for Ocular Therapeutix (NASDAQ:OCUL) after the ...

Taking control of Ocular would also give Sanofi access to its drug delivery platform Elutyx, which could have applications ...

We came across a bullish thesis on Ocular Therapeutix, Inc. on TipRanks’ YouTube channel. In this article, we will summarize ...

Ocular Therapeutix (OCUL) has drawn investor attention after recent trading left the share price at US$11.28. Returns have ...

Sanofi may rebid for Ocular Therapeutix, Inc. to boost retinal therapeutics ahead of Dupixent patent expiry. Click for more ...

Ocular Therapeutix (OCUL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price ...

Ocular Therapeutix is nearing the completion of a head-to-head clinical trial that could be key for the company, investors, ...

Patients with psoriasis are at increased risk for cataracts, uveitis, dry eye disease, glaucoma, retinal vein occlusion (RVO) ...